RxDoctor Payments Data

John Ruggiano, MD

Psychiatry · Cranston, RINPI 1609844240

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 454 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 32.7% of the total. Reporting peaked in 2024 at $1,903 and has fallen 51.4% since, to $925 in 2025. Among psychiatry clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,860in general payments, 2019–2025

Across 454 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Vanda Pharmaceuticals Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Sunovion Pharmaceuticals Inc.$772
  • Otsuka America Pharmaceutical, Inc.$545
  • Supernus Pharmaceuticals, Inc.$425
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$8,860100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,860 in reported general payments places this provider in the 95th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$10,001
Medicare patients
34
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Quetiapine Fumarate114$3,061
Lamotrigine129$2,135
Bupropion XlBupropion Hcl57$1,838
Venlafaxine Hcl ErVenlafaxine Hcl39$1,667
Sertraline Hcl66$1,100
Buspirone Hcl41$1,039
Trazodone Hcl81$813
Divalproex Sodium24$689
Duloxetine Hcl22$579
Fluoxetine Hcl30$495
Mirtazapine26$425
Gabapentin30$384
Hydroxyzine Hcl11$333
Escitalopram Oxalate31$332
Olanzapine23$330

Paid to pharmacies, not to this prescriber.

Other psychiatry in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →